Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 09, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 350,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,430.1125 pence per share.
- Treasury Shares Held: 188,256,678 shares (post-transaction).
- Shares in Issue: 5,796,204,481 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 350,000 shares on August 09, 2006. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 350,000 share repurchase based on the disclosed price of 1,430.1125 pence per share.
- Confirm the updated total share count (5,796,204,481 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial metrics.